Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VSTMthis companyVerastem, Inc.	$8.59	-2.56×	9.35×	17.31×	-1.96×	-135.1%	82.9%	-550.3%	-677.6%	-366.2%	-97.4%	-25.7%	1.34×	0.62×	-149.5×	3.09×	0.0%	4	-7.27	1	D+
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.67	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
BBOTBridgeBio Oncology Therapeutics Inc.	$2.18	-2.91×	0.95×	0×	-0.13×	414.3%	0.0%	0.0%	0.0%	-32.6%	-35.2%	-29.4%	0.01×	2.55×	0×	12.14×	0.0%	0	-0.72	3	B
CCCCC4 Therapeutics, Inc.	$3.19	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
CRDFCardiff Oncology, Inc.	$0.81	-4.07×	4.14×	316.73×	-3.81×	-96.7%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.02	2	C
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
Peer median	—	-2.91×	0.82×	4.4×	-1.4×	-96.7%	77.8%	-265.6%	-240.3%	-40.9%	-58.9%	-29.4%	0.02×	0.51×	0×	7.69×	0.0%	2	-2.78	2	—